Cargando…
Demethylating Agents in the Treatment of Cancer
Gene silencing resulting from aberrant DNA methylation can lead to tumorigenesis. Therefore, drugs that inhibit or interfere with DNA methylation have been used to reactivate and induce silenced gene re-expression in malignancies. Two demethylating agents, azacitidine and decitabine, are approved fo...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4036667/ https://www.ncbi.nlm.nih.gov/pubmed/27713340 http://dx.doi.org/10.3390/ph3072022 |
_version_ | 1782318185407578112 |
---|---|
author | Howell, Paul M. Liu, Zixing Khong, Hung T. |
author_facet | Howell, Paul M. Liu, Zixing Khong, Hung T. |
author_sort | Howell, Paul M. |
collection | PubMed |
description | Gene silencing resulting from aberrant DNA methylation can lead to tumorigenesis. Therefore, drugs that inhibit or interfere with DNA methylation have been used to reactivate and induce silenced gene re-expression in malignancies. Two demethylating agents, azacitidine and decitabine, are approved for the treatment of myelodysplastic syndromes (MDS) by the U.S. Food and Drug Administration (FDA), and are now considered the standard of care in MDS. In this review, we discuss clinical data, including clinical benefits and toxicities, which led to the approval of azacitidine and decitabine. We also summarize findings from clinical trials that used these two demethylating agents in the treatment of solid tumors. Lastly, we discuss some limitations in the use of azacitidine and decitabine in cancer therapy. |
format | Online Article Text |
id | pubmed-4036667 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2010 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-40366672014-05-28 Demethylating Agents in the Treatment of Cancer Howell, Paul M. Liu, Zixing Khong, Hung T. Pharmaceuticals (Basel) Review Gene silencing resulting from aberrant DNA methylation can lead to tumorigenesis. Therefore, drugs that inhibit or interfere with DNA methylation have been used to reactivate and induce silenced gene re-expression in malignancies. Two demethylating agents, azacitidine and decitabine, are approved for the treatment of myelodysplastic syndromes (MDS) by the U.S. Food and Drug Administration (FDA), and are now considered the standard of care in MDS. In this review, we discuss clinical data, including clinical benefits and toxicities, which led to the approval of azacitidine and decitabine. We also summarize findings from clinical trials that used these two demethylating agents in the treatment of solid tumors. Lastly, we discuss some limitations in the use of azacitidine and decitabine in cancer therapy. MDPI 2010-07-02 /pmc/articles/PMC4036667/ /pubmed/27713340 http://dx.doi.org/10.3390/ph3072022 Text en © 2010 by the authors; licensee MDPI, Basel, Switzerland. http://creativecommons.org/licenses/by/3.0/ This article is an Open Access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/). |
spellingShingle | Review Howell, Paul M. Liu, Zixing Khong, Hung T. Demethylating Agents in the Treatment of Cancer |
title | Demethylating Agents in the Treatment of Cancer |
title_full | Demethylating Agents in the Treatment of Cancer |
title_fullStr | Demethylating Agents in the Treatment of Cancer |
title_full_unstemmed | Demethylating Agents in the Treatment of Cancer |
title_short | Demethylating Agents in the Treatment of Cancer |
title_sort | demethylating agents in the treatment of cancer |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4036667/ https://www.ncbi.nlm.nih.gov/pubmed/27713340 http://dx.doi.org/10.3390/ph3072022 |
work_keys_str_mv | AT howellpaulm demethylatingagentsinthetreatmentofcancer AT liuzixing demethylatingagentsinthetreatmentofcancer AT khonghungt demethylatingagentsinthetreatmentofcancer |